Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
The method includes extensive molecular simulations of the target protein alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that considers conformational mobility in both free and complex states. Potential binding pockets are examined on the protein-protein interaction interface and in distant allosteric sites to cover all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00548
UPID:
DLL1_HUMAN
Alternative names:
Drosophila Delta homolog 1
Alternative UPACC:
O00548; B2RAK7; B5M0B3; Q9NU41; Q9UJV2
Background:
Delta-like protein 1, also known as Drosophila Delta homolog 1, plays a pivotal role in cell differentiation, development, and immune system function. It acts as a ligand for NOTCH receptors, facilitating cell communication that regulates cell lineage and morphogenesis. Its involvement in brain development, stem cell maintenance, and immune system development underscores its significance in human physiology.
Therapeutic significance:
Given its role in neurodevelopmental disorders with non-specific brain abnormalities, Delta-like protein 1 presents a promising target for therapeutic intervention. Understanding the role of Delta-like protein 1 could open doors to potential therapeutic strategies.